Previous 10 | Next 10 |
Eidos Therapeutics ( EIDX +13% ) announces positive data from the ongoing open-label extension (OLE) of a Phase 2 study evaluating AG10 in patients with symptomatic transthyretin (TTR) amyloidosis cardiomyopathy (ATTR-CM). The results were presented at the American Heart Association ...
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-...
AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation Rates of All-Cause Mortality (Including Either Death or Cardiac Transplantation, 8.5%) and Cardiovascular Hospitalization (25.5%) Observed in Exploratory Analysis Were Lower than Rates Observed in Placebo-...
Axonics Modulation Technologies (NASDAQ: AXNX ) initiated with Overweight rating at Piper Jaffray. More news on: Axonics Modulation Technologies, Inc., Homology Medicines, Inc., Sarepta Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Eidos Therapeutics (NASDAQ: EIDX ): Q3 EPS of $0.18 may not be comparable to consensus of -$0.27. More news on: Eidos Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN FRANCISCO, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and provided an update on the companyȁ...
The $79 million that Vyndaqel contributed to Pfizer 's (NYSE: PFE) third-quarter revenue doesn't mean a whole lot to the pharmaceutical giant . It amounted to a whopping 0.6% of the company's overall revenue. But you can bet that executives at Alnylam Pharmaceuticals (NASDAQ: ALNY) , Ak...
Original Post Editor's Note : The summary bullets for this article were chosen by Seeking Read more ...
Eidos Therapeutics (NASDAQ: EIDX) has escaped being swallowed up by its parent company, BridgeBio Pharma (NASDAQ: BBIO) . BridgeBio owned 54.5% of Eidos when the latter went public in June 2018; that number grew to 61% by the end of 2018 and has reached 66% today. Thus, the two ...
Agreement Not Reached Between BridgeBio Pharma and Special Committee of Eidos Therapeutics Independent Directors; BridgeBio No Longer Pursuing Acquisition BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that...
News, Short Squeeze, Breakout and More Instantly...
Eidos Therapeutics Inc. Company Name:
EIDX Stock Symbol:
NASDAQ Market:
Eidos Therapeutics Inc. Website:
PALO ALTO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common st...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced that the stockholders of each of BridgeBio and Eidos voted to approve ...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today that the acquisition of shares of common stock of Eidos not held by Br...